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scrutiny as carotid endarterectomy (CEA). Despite the
provision of level I (Grade A) evidence supporting the
role of CEA in symptomatic and asymptomatic
patients,1–4 its role still generates widely conflicting
opinions around the globe. The latest controversies
relate to; (i) recent improvements in the concept of
‘best medical therapy’, (ii) continued scepticism about
the overall generalisability of the operative risks
reported in the international trials and (iii) the
emergence of angioplasty as an alternative to surgery.
This article will focus on an increasingly popular
viewpoint (especially among stroke physicians) that
improvements in best medical therapy (BMT) now
render carotid surgery (and thus by implication,
angioplasty) obsolete.
While the European Carotid Surgery Trial (ECST),
the North American Symptomatic Carotid Endarter-
ectomy trial (NASCET), the Asymptomatic Carotid
Atherosclerosis Study (ACAS) and the Asymptomatic
Carotid Surgery Trial (ACST) were recruiting, the
concept of BMT was relatively primitive. To many
clinicians it simply meant stopping smoking, starting
aspirin and treating hypertension/angina ‘as best
possible’. Few were prescribed lipid-lowering drugs
and many hypertensive patients simply did not
achieve satisfactory control of blood pressure. More-
over, the responsibility for ensuring implementation of
BMT was often delegated to a junior member of the
team.
So what has changed? Improvements in what
currently constitutes ‘modern’ BMT can be summar-
ised as; (i) alternative (dual) antiplatelet therapy, (ii). R. Naylor, MD, FRCS, Department of Surgery, Robert
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using multiple drugs (especially in type II diabetics),
(iii) low dose ACE inhibitor therapy and (iv) statin
therapy. Each of these ‘modern’ agents has been
evaluated in randomised trials and most have shown
a 20–25% relative risk reduction (RRR) in vascular
death or non-fatal myocardial infarction and stroke.5–7
There is, therefore, no doubt that the ‘modern’ concept
of BMT has the potential to greatly reduce long term
cardiovascular risk but, in the absence of any
randomised trials against CEA (and with none likely
in the future), the current debate has to focus on; (i)
how well is BMT tolerated or implemented in the ‘real
world’ and (ii) how do the results from the newer
medical trials compare with those of ECST, NASCET,
ACAS and ACST regarding the magnitude of
reduction in the absolute risk of stroke and the
immediacy of benefit.
In an ‘ideal’ world, patients would be aware of the
importance of taking their medications as prescribed,
none would have side effects, all patients would have
equal access to treatment, all would turn up to obtain
repeat prescriptions and all medications would, of
course, confer immediate benefit without requiring
any lag phase. Unfortunately, we live in an imperfect
world. Only 5% of diabetics think that stroke is a
serious complication of their condition.8 Only about a
quarter of hypertensive patients in the US achieve a
target blood pressure of !140/90 mmHg while, in
some countries (e.g. England), this figure is !10%.7
From a practical point of view, up to 40% of known
hypertensives destined to suffer a stroke will not be
on any treatment in the year prior to stroke onset and
only 50% of those actually receiving treatment will
have one documented diastolic blood pressure
!90 mmHg.9 Similarly, while evidence suggests that
multiple drug therapy for hypertension is preferableEur J Vasc Endovasc Surg 28, 457–461 (2004)
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poorer if the patient has to take more than one tablet10
and about 50% of patients will cease their anti-
hypertensive therapy following completion of the
research trials within which they were randomised.11
The situation is no different with respect to the role
of statin therapy, currently viewed by many phys-
icians as the ‘trump card’ in the modern concept of
BMT following publication of the British Heart
Protection Study,6 despite the fact that the most recent
subgroup analysis from this trial has showed that
Simvastatin did not confer any reduction in late stroke
in patients with pre-existing symptomatic cerebral
vascular disease.12 In order to achieve the overall
cardiovascular benefits reported in the original Heart
Protection Study,6 the patient had to be on statin
therapy for 5 years. However, in the ‘real world’
adherence rates can be as low as 40% at 2 years in
patients who have suffered an acute coronary syn-
drome and who might otherwise be expected to be
highly motivated towards preventing further cardio-
vascular events. More worrying, only 17–32% of
patients suffering an acute coronary event are dis-
charged on statin therapy from the outset13,14 and only
50% of patients who are given a prescription will
actually be taking the drug.15 In short, secondary care
clinicians (and surgeons) are generally poor at
prescribing statins and implementing aggressive
hypertensive therapy after heart attacks and strokes.
Moreover, many patients prescribed statins or anti-
hypertensive therapy do not get the medication from
their pharmacist and most of those that do start
treatment are reluctant to continue with it long term.
The inevitable ‘lag phase’ for BMT to exert its
beneficial effect is another important but often
forgotten component in the debate. It has been
suggested that the frequency of haemorrhagic stroke
decreases within a year of implementing optimal anti-
hypertensive therapy, but that ischaemic stroke only
starts to decline during the second year when blood
pressure control thresholds are achieved.16 In the
Heart Protection Study, the reduction in stroke only
became significant at the end of the second year of
treatment with a statin.12,17 However, the median
‘persistence’ on statin therapy (i.e. how long continu-
ously were the patients taking their medication) in
39,222 statin users in Umbria was only 5.3 months.18
Simple maths shows that this is only one twelfth the
length of the 5-year study period reported in the
British Heart Protection Study.6
The third factor to be considered in this debate is the
actual magnitude of risk reduction and how it is
reported in the literature. It has become conventional
in the medical trials (especially in overviews andEur J Vasc Endovasc Surg Vol 28, November 2004abstracts) to predominantly report the relative
reduction in stroke or vascular risk. For the most
part, the relative reduction in risk has usually been
about 20–25% for stroke. In the ECSTandNASCET, the
equivalent RRR was 45% and 69%, respectively.1,2
Corresponding data for asymptomatic patients in
ACAS and ACST were 54% and 45%.3,4 This mode of
presenting RRR data can, however, be quite mislead-
ing. For example, in the Heart Protection Study, it was
observed that statin therapy conferred a significant
50% RRR in the subsequent need for CEA.6 However,
if the reader looks beyond the ‘headline’ news, it
becomes clear that the requirement for CEA in patients
randomised to statin therapy was 0.4% at 5 years, as
compared to 0.8% in placebo patients (pZ0.0003). The
RRR conferred by statin therapy was certainly 50%,
but the ARR was only 0.4% at 5 years!
Accordingly, if one now compares the reductions in
absolute risk of stroke by the various therapeutic
options comprising the modern concept of BMT, it is
possible to see just how much benefit is achievable,
bearing in mind that most conferred a 20–25% RRR in
stroke (Table 1). Clopidogrel was associated with a
0.9% ARR in ischaemic stroke at 2 years in patients
presenting initially with a stroke.5 This equates to 111
patients having to be treated for 2 years to prevent one
ischaemic stroke, while treating 1000 patients for 2
years would prevent only nine strokes. Interestingly,
theMATCH study (Clopidogrel alone versusAspirinC
Clopidogrel in patients with a prior history of stroke/
TIA) showed no evidence that combination antiplate-
let therapy reduced the long-term risk of stroke.19
Similarly, 5 years of statin therapy conferred an ARR of
only 1.4% in stroke,6 while low dose ACE-inhibitor
therapy (4 mg Perindopril) conferred a 2.3% ARR in
stroke at 4 years in patients who presented initially
with TIA or stroke.20 Finally, aggressive control of
blood pressure in Type II diabetics was associated with
a 44% reduction in stroke at 8 years but the ARR was
only 3.7%.21
How does CEA compare with regard to the
reduction in absolute risk of stroke? Table 1 summar-
ises comparable data from each of the major trials
regarding the number needed to treat to prevent one
stroke (NNT) and the number of strokes prevented per
1000 CEAs. In ECST, CEA conferred an ARR of 8.5% at
5 years in patients with 70–99% stenoses (NNTZ12, 83
ipsilateral ischaemic strokes prevented per 1000
operations). Parallel ARR data for NASCET patients
with 70–99% stenoses (i.e. broadly equivalent to an
ECST 85–99% stenosis) were 19.4% at 3 years (200
ipsilateral strokes prevented at 3 years). Carotid
endarterectomy for asymptomatic disease conferred
a lower ARR than in symptomatic patients (ACASZ
Table 1. Prevention of ischaemic stroke: comparison of recent trials of best medical therapy and the international surgical trials
Study Intervention Recruits ARR%/RRR% NNT Strokes prevented
per 1000 patients
CAPRIE 75 mg Clopidogrel
vs. 325 mg Aspirin
Stroke 0.9/8 at 2 years 111 9 at 2 years
BHP 40 mg Simvastatin
vs. placebo
All CVD 1.4/25 at 5 years 71 12 at 5 years
PROGRESS 4 mg Perindopril
vs. placebo
TIA/CVA 2.3/33 at 4 years 43 23 at 4 years
UKPDS HT RX in type II
DM
HTCDM 3.7/44 at 8 years 27 37 at 8 years
ACST immediate CEA vs.
BMT
Asymptomatic 5.3/46 at 5 years 19 53 at 5 years
ACAS immediate CEA vs.
BMT
Asymptomatic 5.9/54 at 5 years 17 59 at 5 years
NASCET 50–69% immediate CEA vs.
BMT
TIA/stroke 6.5/29 at 3 years 15 67 at 3 years
ECST 70–99% immediate CEA vs.
BMT
TIA/stroke 8.5/45 at 5 years 12 83 at 5 years
NASCET 70–99% immediate CEA vs.
BMT
TIA/stroke 19.4/69 at 3 years 5 200 at 3 years
NASCET 70–99% CEA patients aged
O75 years
TIA/stroke 28/88 at 2 years 3 303 at 2 years
CETC 70–99% CEA patients ran-
domised!2 wks of
event
TIA/stroke 30/80 at 3 years 3 303 at 3 years
NASCET 70–99% CEA patients with
contralateral occlu-
sion
TIA/stroke 47/68 at 2 years 2 500 at 2 years
NASCET 70–99% CEA patients with
ulcerated 95% ste-
nosis
TIA/stroke 54/74 at 2 years 2 500 at 2 years
CVD, cardiovascular disease; TIA, transient ischaemic attack; CVA, stroke; HT, hypertensive patients; DM, type II diabetics; CEA, carotid
endarterectomy; BMT, best medical therapy; NNT, number needed to treat to prevent one stroke at the specified time period; CETC, Carotid
Endarterectomy Triallists Collaboration; ARR, actual risk reduction; RRR, relative risk reduction. For example, the British Heart Protection
Study showed that 40 mg Simvastatin conferred a 25% relative risk reduction in ischaemic stroke at 5 years in patients with ‘cardiovascular
symptoms’. However, this only equates to a 1.4% absolute difference in risk and 71 patients have to be treated for 5 years to prevent one
ischaemic stroke. Treating 1000 patients with Simvastatin for 5 years will prevent 12 ischaemic strokes.
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an overview of the secondary analyses from the
symptomatic trials22 has shown that one of the key
advantages favouring CEA is the very much greater
ARR in selected, high-risk patients (Table 1). Carotid
endarterectomy conferred a 28% ARR in stroke in
NASCET patients aged over 75 with a 70–99% stenosis.
In clinical terms, this means that only three patients
need to undergo CEA to prevent one stroke and 303
ipsilateral strokes will be prevented per 1000 CEAs.
Carotid surgery conferred an even greater benefit in
patients with contralateral occlusion (ARRZ47% at 2
years) and in patients with a 90–95% stenosis and
plaque irregularity/ulceration (ARRZ54% at 2 years).
In both the latter subgroups, only two patients have to
undergo CEA to prevent one stroke and 500 ipsilateral
strokes are prevented per 1000 CEAs.
In summary, there have undoubtedly been major
advances in BMT and these should be seen to
complement CEA in most patients. It might be argued
that BMTcould threaten the role of CEA or angioplasty
in asymptomatic patients, but not if the rates ofpersistence and compliance remain poor. Put simply,
if the drugs are not being taken for sustained periods
of time, they cannot confer any benefit. Moreover,
BMT will never achieve comparable benefit in the
more high-risk subgroups. Finally, there is one
absolute reason why improvements in the ‘modern
concept’ of BMTwill not render CEA obsolete. This is,
quite simply, because CEA confers immediate benefit.
Best medical therapy inevitably requires a lag-phase.
The Carotid Endarterectomy Triallists Collaboration
(CETC) performed an overview of the pooled data
from NASCET and ECST.23 This showed that CEA
conferred a 30% ARR in stroke (RRRZ80%), provided
the patient was randomised within two weeks of the
clinical event. On average, patients waited a further 5–
7 days for surgery (P. M. Rothwell, personal com-
munication). If surgery was delayed (for whatever
reason), the overall benefit rapidly diminished (18%
ARR at 3 years for patients in whom 2–4 weeks
elapsed between event and randomisation, 11% ARR
at 4–12 weeks and only 9% if 12Cweeks elapsed). In
practical terms (i.e. taking into account the inevitableEur J Vasc Endovasc Surg Vol 28, November 2004
Table 2. Effect of operative risk on prevention of ipsilateral, ischaemic stroke
Study 30 day operative
risk*(%)
ARR%/RRR(%) NNT Strokes prevented per
1000 CEAs
(a) Symptomatic patients
ECST 70–99% 0 13.1/86 at 3 years 8 132
ECST 70–99% 2 11.1/73 at 3 years 9 112
ECST 70–99% 4 9.1/60 at 3 years 11 92
ECST 70–99% 6 7.1/47 at 3 years 14 72
ECST 70–99% 8 5.1/34 at 3 years 19 52
ECST 70–99% 10 3.1/21 at 3 years 32 32
(b) Asymptomatic patients
ACST 60–99% 0 8.2/69 at 5 years 12 83
ACST 60–99% 1 7.2/61 at 5 years 14 71
ACST 60–99% 2 6.2/53 at 5 years 16 63
ACST 60–99% 3 5.2/44 at 5 years 19 53
ACST 60–99% 4 4.2/35 at 5 years 24 42
ACST 60–99% 5 3.2/27 at 5 years 31 32
ACST 60–99% 6 2.2/19 at 5 years 45 22
ECST, European Carotid Surgery Trial; ACST, Asymptomatic Carotid Surgery Trial.
* Thirty day operative riskZdeath/any stroke within 30 days of surgery. i.e. If a surgeon has an operative risk (30-day death/stroke rate)
following endarterectomy of 2%, the RRR in late stroke is 73% and 112 ipsilateral ischaemic strokes will be prevented at 3 years per 1000 CEAs
performed. However, if the operative risk were as high as 10%, the RRR is now only 21% and only 32 strokes will be prevented at three years
by operating upon 1000 patients.
A. R. Naylor460delay to operation after presentation), this essentially
equates to 303 strokes being prevented at three years
per 1000 CEAs if the operation is performed within
one month of the most recent event as compared with
only 89 strokes prevented at 3 years if surgery is
delayed for O3 months after the event.
However, a surgeon cannot simply justify his/her
practice on the data from the international trials
without knowing and quoting his/her personal out-
comes. Accordingly, an individual surgeon’s operative
risk is another important risk factor for stroke and has
to be taken into account when deciding whether a
patient is best treated by surgery or BMT. Table 2
summarises how a surgeon’s operative risk modifies
the effect of CEA on stroke prevention. If a surgeon
performs 1000 CEAs in symptomatic patients with an
operative risk of 2%, 112 ipsilateral, ischaemic strokes
will be prevented at 3 years. However, if the risk were
to increase to 10% (as happened to both the surgery
and angioplasty arms in the CAVATAS study24 and in
patients undergoing protected angioplasty in the EVA-
3S study,25), only 32 strokes will be prevented at 3
years, i.e. dubious clinical benefit. Similarly, the
operative risk has an equally important role in
deciding whether asymptomatic patients might ben-
efit from surgery (or angioplasty). A surgeon who
performs 1000 CEAs in asymptomatic patients with an
operative risk of 2% will confer a 53% RRR in late
stroke and 63 strokes will be prevented at 5 years.
However, if the operative risk were to increase to 6%
(as was the case for both CEA and angioplasty in the
SAPPHIRE study26), the RRR falls to 19%, 45 pro-
cedures would have to be performed to prevent one
stroke and only 22 strokes would be prevented at 5Eur J Vasc Endovasc Surg Vol 28, November 2004years by operating upon 1000 patients, i.e. 978 patients
would have undergone an unnecessary (and poten-
tially dangerous) procedure.
In conclusion, the modern concept of BMT will
continue to complement, rather than replace, CEA,
provided; (i) someone takes responsibility for ensuring
BMT is implemented properly and (ii) surgery is
performedwithin weeks of the presenting event with a
lowmorbidity andmortality. However, the single most
important factor supporting the continued role of
surgery in the future is the immediate benefit it
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